Skip to main content

Table 4 CXCR4 and CXCL12 status in primary tumors, regional and distant metastases of cats with mammary carcinoma, stratified accordingly to the molecular subtype of the primary tumor

From: CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors

  Primary tumor Regional metastases Distant metastases
Luminal A CXCR4
 Negative 1/13 (7.7) 2/4 (50.0) 2/3 (66.7)
 Positive 12/13 (92.3) 2/4 (50.0) 1/3 (33.3)
CXCL12
 Negative 5/13 (38.5) 0/4 (0.00) 0/3 (0.00)
 Positive 8/13 (61.5) 4/4 (100) 3/3 (100)
Luminal B CXCR4
 Negative 3/31 (9.7) 5/15 (33.3) 3/4 (75.0)
 Positive 28/31 (90.3) 10/15 (66.7) 1/4 (25.0)
CXCL12
 Negative 8/32 (25.0) 0/15 (0.00) 0/4 (0%)
 Positive 24/32 (75.0) 15/15 (100) 4/4 (100)
Luminal B-HER2+/HER2+ CXCR4
 Negative 7/31 (22.6) 2/13 (15.4) 0/5 (0.0)
 Positive 24/31 (77.4) 11/13 (84.6) 5/5 (100)
CXCL12
 Negative 6/30 (20.0) 2/14 (14.3) 0/5 (0.0)
 Positive 24/30 (80.0) 12/14 (85.7) 5/5 (100)
Triple negative CXCR4
 Negative 9/38 (23.7) 5/15 (33.3) 7/13 (53.9)
 Positive 29/38 (76.3) 10/15 (66.7) 6/13 (46.1)
CXCL12
 Negative 6/39 (15.4) 0/15 (0.0) 0/13 (0.00)
 Positive 33/39 (84.6) 15/15 (100) 13/13 (100)
  1. HER2+ HER2-overexpressing subtype